HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal ...

Comprehensive genetic testing using multigene testing panels for prostate cancer can arm genetic counselors with the information they need to guide precision therapy, even in men with early stage ...

Multigene tests are an integral component of new policy initiatives such as the US National Institutes of Health (NIH) Precision Medicine Initiative and the US National Cancer Institute Cancer ...

Patients with non–small cell lung cancer (NSCLC) who tested positive for driver gene alteration had longer overall survival when given targeted therapy. Multigene testing should be utilized more to ...

Allison W. Kurian offers insight on using multigene panel testing to discover breast and ovarian cancer risks that may have otherwise went undetected. Multigene panel sequencing detected ovarian ...

Current guidelines for genetic testing in women with breast cancer are based on established family history or clinical guidelines but miss approximately 50% of carriers who fall below the clinical ...

A multigene panel test could be a useful diagnostic tool to help clinicians identify patients with a hereditary kidney cancer syndrome, according to the results of a study published in Cancer. "We ...

MAYWOOD, Ill. -- A major study published in the New England Journal of Medicine is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can ...

A major study published in the New England Journal of Medicine is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid ...

According to a new analysis, racial minorities, the uninsured, and individuals treated at community cancer programs had worse odds of receiving MGT. By comparison, rates of accessing MGT increased ...

SAN FRANCISCO, April 2, 2019 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading genetics company, will present data from more than 113,000 patients that support updating genetic testing ...